Payment overview · 2025
General Payments
$671.88
6 reported records · 2 companies
Healthcare provider profile · identity verified
Salman Zafar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NORWICH, CT · NPI 1457319998
Verified facts
What the public records show
CMS Open Payments records show Salman Zafar, MD received $671.88 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 82.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $552.63 | 82.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $119.25 | 17.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $671.88 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $435.35 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $119.25 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1023 | 275 |
| Amlodipine Besylate | Amlodipine Besylate | 590 | 151 |
| Lisinopril | Lisinopril | 545 | 144 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 433 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 430 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 102 |
| Losartan Potassium | Losartan Potassium | 319 | 78 |
| Gabapentin | Gabapentin | 284 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 261 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 49 |
| Ezetimibe | Ezetimibe | 206 | 60 |
| Metformin Hcl | Metformin Hcl | 202 | 61 |
| Omeprazole | Omeprazole | 199 | 57 |
| Furosemide | Furosemide | 191 | 54 |
| Simvastatin | Simvastatin | 190 | 52 |
| Metformin Hcl Er | Metformin Hcl | 186 | 51 |
| Alprazolam | Alprazolam | 184 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 44 |
| Alendronate Sodium | Alendronate Sodium | 176 | 50 |
| Montelukast Sodium | Montelukast Sodium | 165 | 39 |
| Lovastatin | Lovastatin | 159 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 20 |
| Trazodone Hcl | Trazodone Hcl | 154 | 28 |
| Eliquis | Apixaban | 149 | 29 |
| Sertraline Hcl | Sertraline Hcl | 147 | 42 |
| Allopurinol | Allopurinol | 146 | 34 |
| Meloxicam | Meloxicam | 144 | 44 |
| Jardiance | Empagliflozin | 141 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 69 |
| Carvedilol | Carvedilol | 101 | 28 |
| Ozempic | Semaglutide | 101 | 21 |
| Clonazepam | Clonazepam | 95 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 95 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 26 |
| Atenolol | Atenolol | 85 | 14 |
| Azithromycin | Azithromycin | 83 | 70 |
| Glimepiride | Glimepiride | 83 | 21 |
| Farxiga | Dapagliflozin Propanediol | 82 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 20 |
| Bupropion Xl | Bupropion Hcl | 76 | 19 |
| Finasteride | Finasteride | 76 | 15 |
| Potassium Chloride | Potassium Chloride | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 16 |
| Pregabalin | Pregabalin | 71 | 17 |
| Famotidine | Famotidine | 70 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 19 |
| Lorazepam | Lorazepam | 66 | 14 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Mirtazapine | Mirtazapine | 63 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 58 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 53 | 16 |
| Baclofen | Baclofen | 52 | suppressed |
| Prednisone | Prednisone | 52 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 14 |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Levofloxacin | Levofloxacin | 41 | 38 |
| Celecoxib | Celecoxib | 39 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 39 | 11 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Methylprednisolone | Methylprednisolone | 35 | 33 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 27 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 15 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Hydroxyurea | Hydroxyurea | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 11 |
| Colchicine | Colchicine | 25 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Livalo | Pitavastatin Calcium | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Lidocaine | Lidocaine | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $671.88 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Ozempic | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error